Filing Flows › Biocryst Pharmaceuticals (BCRX) › Operating margin
Biocryst Pharmaceuticals (BCRX) operating margin by quarter
Biocryst Pharmaceuticals' operating margin was 29.6% in Q3 2026 (third quarter 2026), -15.5 pts from Q2 2026. Over the last 6 quarters it ranged from 14.6% (Q1 2025) to 64.0% (Q4 2025).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 29.6% | -15.5 pts | +11.0 pts |
| Q2 2026 | 45.1% | -18.9 pts | +26.9 pts |
| Q4 2025 | 64.0% | +45.5 pts | — |
| Q3 2025 | 18.6% | +0.3 pts | — |
| Q2 2025 | 18.2% | +3.6 pts | — |
| Q1 2025 | 14.6% | — | — |
Q3 2026 at a glance
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Biocryst Pharmaceuticals' operating margin?
Biocryst Pharmaceuticals' operating margin was 29.6% in Q3 2026 (third quarter 2026), -15.5 pts from Q2 2026.
How has Biocryst Pharmaceuticals' operating margin changed?
Over the last 6 quarters it ranged from 14.6% (Q1 2025) to 64.0% (Q4 2025).
Q3 2026 results → · How Biocryst Pharmaceuticals makes money →